share_log

君实生物(688180.SH):特瑞普利单抗二线及以上治疗黑色素瘤获得国家药监局常规批准

JUNSHI BIO (688180.SH): Trelagliptin for second-line and above treatment of melanoma has obtained regular approval from the National Medical Products Administration.

Gelonghui Finance ·  Jan 6 10:33

On January 6th, Gloronghui reported that JUNSHI BIO (688180.SH) announced that it received the "Pharmaceutical Supplement Application Approval Notification" issued by the National Medical Products Administration (referred to as "National Drug Administration"). The indication for Trepulimab (trade name: Tuoyi, product code: JS001) for the treatment of unresectable or metastatic melanoma that has previously failed systemic therapy has been agreed by the National Drug Administration, and its conditional approval has been converted to regular approval.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment